Gepirone ER "not approvable" for MDD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fabre-Kramer Pharmaceuticals/GlaxoSmithKline's potential first-in-class 5HT1a agonist gepirone extended release is "not approvable" for adults with major depressive disorder, the companies say Nov. 2. The NDA rejection is the third for the therapy, which was denied by FDA in 2002 and 2004 while it was licensed to Organon (1Pharmaceutical Approvals Monthly July 1, 2004, p. 26). FKP took the antidepressant back in 2005. The Houston firm inked a development and commercialization deal with GSK in February...
You may also be interested in...
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.